diaDexus (DDXSQ) Stock Price, News & Analysis

Company Overview

diaDexus is a molecular diagnostics company focused on the development and commercialization of immunodiagnostic assays for risk assessment of cardiovascular and chronic inflammatory diseases. The company’s flagship offering is the PLAC test family, which measures lipoprotein-associated phospholipase A2 (Lp-PLA2), a biomarker linked to vascular inflammation and plaque instability. These tests are designed to complement traditional lipid panels and provide clinicians with additional information to identify patients at elevated risk for atherosclerotic cardiovascular events.

Headquartered in South San Francisco, California, diaDexus maintains laboratory facilities in the San Francisco Bay Area and holds regulatory clearances, including U.S. FDA approval and CE marking for its PLAC assays. The company serves clinical laboratories, hospitals and research institutions across North America and Europe through a network of distribution and laboratory partnerships. In addition to its cardiovascular portfolio, diaDexus leverages its immunoassay platform to advance new biomarker candidates for conditions such as sepsis, oncology and autoimmune disorders.

Founded in 1999, diaDexus has built its expertise through collaborations with academic centers and industry partners to validate novel biomarkers and expand its pipeline. Over the years, the company has pursued strategic alliances to support assay development, clinical validation and market access. diaDexus’s management team brings together professionals with backgrounds in diagnostics, clinical chemistry and regulatory affairs, guiding the company’s efforts to deliver actionable diagnostic solutions for patient risk stratification and disease management.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 100 shs
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Company Calendar

• Today: 6/08/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: MED PRODUCTS
• Sub-Industry: Business Services
• Current Symbol: OTCMKTS:DDXSQ
• CIK: N/A
• Web: www.diazyme.com
• Phone: 858-455-4768
• Fax: 650-246-6499
• Employees: 38
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A